This startup develops non-invasive, PCR-based liquid biopsy tests for early cancer detection. Their technology analyzes a single sample to identify cancer, enabling earlier diagnosis and improved patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Early cancer detection is critical for improving patient outcomes, but current methods often rely on invasive procedures or lack the sensitivity to detect cancer at its earliest stages. Traditional diagnostic tests can also be expensive and require specialized facilities, limiting accessibility, particularly in low- to middle-income countries.
Solution
Light-Hope Diagnostics develops non-invasive, PCR-based in-vitro diagnostic (IVD) tests for the early detection of multiple cancers through liquid biopsy. Their innovative multiplex PCR technology enables the simultaneous detection of multiple cancer-specific RNAs in a single serum sample, providing precise and efficient diagnostics. The company's proprietary formulation and freeze-drying method stabilizes IVD products at higher ambient temperatures, eliminating the need for cold chain management and significantly reducing costs. This approach aims to make advanced cancer diagnostics affordable and accessible worldwide, especially in regions with limited resources. Light-Hope Diagnostics is currently performing analytical and clinical validation of its first IVD product for early diagnosis of breast cancer and has ongoing projects for ovarian, lung, pancreatic, and prostate cancer.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and individuals seeking early and non-invasive cancer detection methods, particularly in low- to middle-income countries.
Features
- Non-invasive liquid biopsy approach using serum samples
- Multiplex PCR technology for simultaneous detection of multiple cancer-specific RNAs
- Proprietary freeze-drying method for long-term stabilization of IVD products at higher ambient temperatures
- Cost-effective diagnostics due to elimination of cold chain requirements
- IVD products for early detection of breast, ovarian, lung, pancreatic, and prostate cancers
- Development of a Multi-cancer Early Detection (MCED) test to simultaneously detect at least five major forms of human cancer